Find G207 manufacturers, exporters & distributors on PharmaCompass

G207

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

API REF. PRICE (USD/KG)

$ 0

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Regulatory FDF Prices

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

API

FDF

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Wf8nwa83re, G 207, G 207 [who-dd], G207, G-207, 80156-87-2

Molecular Formula

C₂₅H₂₈N₄O

Molecular Weight

400.5 g/mol

InChI Key

ZUGKFNYCFBDWIO-UHFFFAOYSA-N

FDA UNII

WF8NWA83RE

G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.

1 2D Structure

G207

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(4-butylphenyl)-[4-[(4-propoxyphenyl)diazenyl]phenyl]diazene

2.1.2 InChI

InChI=1S/C25H28N4O/c1-3-5-6-20-7-9-21(10-8-20)26-27-22-11-13-23(14-12-22)28-29-24-15-17-25(18-16-24)30-19-4-2/h7-18H,3-6,19H2,1-2H3

2.1.3 InChI Key

ZUGKFNYCFBDWIO-UHFFFAOYSA-N

2.2 Other Identifiers

2.2.1 UNII

WF8NWA83RE

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Wf8nwa83re

2. G 207

3. G 207 [who-dd]

4. G207

5. G-207

6. 80156-87-2

7. 2136340-90-2

8. 162320-00-5

9. Unii-wf8nwa83re

10. Schembl12425118

11. Schembl24849964

12. Dtxsid70612659

13. Zugkfnycfbdwio-uhfffaoysa-n

14. (e)-1-(4-butylphenyl)-2-{4-[(e)-(4-propoxyphenyl)diazenyl]phenyl}diazene

2.4 Create Date

2007-12-05

3 Chemical and Physical Properties

Molecular Formula	C₂₅H₂₈N₄O
Molecular Weight	400.5 g/mol
XLogP3	8.2
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	10
Exact Mass	Da
Monoisotopic Mass	Da
Topological Polar Surface Area	58.7
Heavy Atom Count	30
Formal Charge	0
Complexity	499
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in brain cancer.

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

G207, Cancer killing viruses are modified to make them utilizable as a therapeutic agent in human by switching off certain genes that normally enable the virus to multiply in healthy cells, which would destroy these cells. As a result of this genetic modification, the HSVs are able to reproduce in tumor cells solely, since only this offer an environment that compensates for the loss of the removed viral genes. Consequently, the virus is able to replicate in the tumor cells, selectively destroying them without harming healthy tissue.

Drugs in Development